You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
An MD Anderson-led team also used longitudinal single-cell sequencing to show how clonal architecture changed in response to AML treatment.
In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.
The aggressive subtype, uncovered by a team of researchers in Germany, may also be susceptible to targeted therapy that blocks interferon signaling.
Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision.
In Nature this week: molecular profiling platform identifies treatments for pediatric cancer cases, metaFlye algorithm addresses challenges of long-read metagenomic assembly, and more.
In Science this week: somatic mutation heterogeneity among human bladder samples, and more.
The strategy promises to offer patients the best possible predictive, preventative, and personalized care underpinned by genome sequencing.
In two studies at ESMO, researchers demonstrated the ability of combined biomarker approaches to predict the efficacy of immune checkpoint inhibitors.
A Lund University-led team developed two methylation risk scores to predict which patients would or would not respond to treatment and experience side effects.
The findings suggested that genomic surveillance of Barrett's esophagus could identify patients who will progress years in advance and enable earlier treatment.
According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.
A number of United Nations agencies push for scientific findings to be made accessible through open science.
Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.
In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.